Topical Glutamate Diacetate: A Promising Therapy for Post-Coronavirus Disease 2019 Olfactory Dysfunction Through Calcium Modulation.

Publication date: Jun 04, 2025

BackgroundOlfactory dysfunction is a frequent symptom experienced by individuals recovering from coronavirus disease 2019 (COVID-19) and significantly impacts daily life activities. Recent studies suggest that reducing nasal calcium levels may help restore olfactory function. Glutamate diacetate (GLD) is a natural sequestering agent that binds calcium ions and may offer therapeutic benefits in managing post-COVID olfactory dysfunction. ObjectiveThis study aimed to evaluate the effectiveness of topical GLD treatment in reducing nasal calcium levels and improving olfactory function in individuals with chronic olfactory dysfunction following COVID-19. MethodsA double-blind, placebo-controlled trial was conducted with 66 participants who were randomized into two groups: GLD (1% solution) and saline placebo (0. 9% solution). Participants received nasal treatment three times daily for six months. Olfactory function was assessed using the Sniffin’ Sticks test, measuring threshold (T), discrimination (D), and identification (I) scores. Nasal calcium levels were also measured. Statistical analysis included independent t-tests and change-from-baseline comparisons. ResultsSignificant improvements were observed in the GLD group across olfactory assessments. By month 6, threshold scores increased by 0. 78 +/- 0. 15, discrimination scores by 0. 72 +/- 0. 15, and identification scores by 1. 80 +/- 0. 15, all exceeding gains in the saline group. Nasal calcium levels decreased significantly in the GLD group (7. 36 +/- 1. 21 mM vs 2. 49 +/- 0. 51 mM in saline), suggesting a contribution mechanism in olfactory improvement. ConclusionGLD treatment resulted in statistically significant improvements in olfactory function and a reduction in nasal calcium levels in individuals with post-COVID olfactory dysfunction. However, the observed changes did not reach the threshold for clinical significance. These findings suggest a potential role for GLD in olfactory recovery, but further studies are needed to evaluate its long-term efficacy and clinical relevance.

Concepts Keywords
Allergy calcium
Calcium controlled trial
Coronavirus coronavirus disease 2019
Month discrimination
Therapy glutamate diacetate
identification
olfactory dysfunction
sequestering agent
Sniffin’ sticks
threshold

Semantics

Type Source Name
disease MESH Coronavirus Disease 2019
drug DRUGBANK Calcium
disease IDO symptom
drug DRUGBANK Calcium cation
disease MESH clinical significance
disease IDO role

Original Article

(Visited 1 times, 1 visits today)